← All trials
NCT07037043
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2025
- Primary completion
- May 31, 2028
- Completion date
- Jun 30, 2028
- First posted
- Jun 25, 2025
- Last posted
- Jul 2, 2025
- Enrollment
- 196
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Picardie Jules VerneLead sponsor
- Rouen Normandy UniversityCollaborator
- University of LilleCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.